Fig. 1From: ‘DURVIT’: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironmentDURVIT study timeline. SN = sentinel lymph nodeBack to article page